Clinical Trial Search

Primary: Number of Participants With Progression at the 3 Month Follow up Visit — 15; 7 participants

Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants

Primary: Objective Response Rate (ORR) — 3.92 Participants (%)

Primary: Progression-free Survival (PFS) — 5.257 months

Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders

Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants

Primary: Overall Survival — 13.4 month

Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 3 participants

Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012

Primary: Objective Response Rate — 15 Participants

Primary: Overall Survival — 4.8 months

Primary: Response Rate — 0 percentage of patients responding

Primary: RR — 15 Participants

Primary: Disease Control Rate — 9 Participants

Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants

Primary: Time to Progression — 4.50; 7.66; 5.55 Months

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months

Primary: Progression-Free Survival (PFS) — 3.8 months

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: Progression Free Survival (PFS) by Investigator Assessment — 3.7; 2.1 Months — p== 0.1428

Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants

Primary: Overall Response Rate — 0.029 proportion of paticipants

Primary: Progression Free Survival(PFS) — 2.6; 1.8 month

Primary: Response Rate — 28.9; 26.1 percentage of participants

Primary: Dose Limiting Toxicity and Maximum Tolerated Dose of Olaparib (Phase I) — 0; 1 Participants

Primary: Best Overall Response — 0; 2; 25; 42 participants

Primary: Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis — 6.57; 7.52; 7.10; 7.39 months — p== 0.56